SCHEMBL2256179

SCHEMBL2256179

CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)c1cccc(F)n1.CC(C)(C)OC(=O)Nc1cccc(F)n1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FFAR2 O15552 1/20 0.37
SCN9A Q15858 3/20 0.37
GRM5 P41594 4/20 0.36
LCK P06239 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C9 P11712 2/20 0.35
SYK P43405 1/20 0.35
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
CYP3A4 P08684 1/20 0.34
ATR Q13535 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
GSK3B P49841 1/20 0.33
DYRK1A Q13627 1/20 0.33
NPC1 O15118 1/20 0.33
GAA P10253 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2250438 0.87 FFAR2 (0.45) FFAR2SCN9AGRM5LCKCYP1A2
SCHEMBL2248255 0.87 SSTR4 (0.36) SYKLMNAPOLBMEN1KMT2A
SCHEMBL29394473 0.77 LCK (0.47) LCKPOLBMEN1KMT2AGSK3B
SCHEMBL16790976 0.75 BCHE (0.49)
SCHEMBL959885 0.72 GRM5 (0.38) GRM5LCKSYKMEN1KMT2A
SCHEMBL943797 0.72 SSTR4 (0.37) GRM5SYKMEN1KMT2ANPC1
SCHEMBL22523913 0.72 LCK (0.43) SCN9ALCKSYKATRMEN1
SCHEMBL31151002 0.72 RAB9A (0.62) GRM5MEN1KMT2ANPC1RAB9A
SCHEMBL533505 0.72 RAB9A (0.62) GRM5MEN1KMT2ANPC1RAB9A
SCHEMBL14622117 0.72 LCK (0.43) SCN9ALCKPOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110206607-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LIMITED (GB) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206607-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS CNR1, CNR2, GPR18 FFAR2 143/4885SCN9A 1113/4885GRM5 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.